TrialDiabetes, obesity & metabolism2018

Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.

Claire C J Dekkers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.